找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Leadership as Identity; Constructions and De Jackie Ford,Nancy Harding,Mark Learmonth Book 2008 Palgrave Macmillan, a division of Macmillan

[復制鏈接]
查看: 55973|回復: 41
樓主
發(fā)表于 2025-3-21 16:07:54 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Leadership as Identity
副標題Constructions and De
編輯Jackie Ford,Nancy Harding,Mark Learmonth
視頻videohttp://file.papertrans.cn/583/582307/582307.mp4
圖書封面Titlebook: Leadership as Identity; Constructions and De Jackie Ford,Nancy Harding,Mark Learmonth Book 2008 Palgrave Macmillan, a division of Macmillan
描述Management has failed; its successor is leadership. Can leadership fulfil the promises that are made in its name? This book is written for those charged with being leaders, and?uses poststructuralist theory to provide a language for the confusions and uncertainties that leadership can often bring.
出版日期Book 2008
關鍵詞leadership; learning; management; success
版次1
doihttps://doi.org/10.1057/9780230584181
isbn_softcover978-1-349-35442-9
isbn_ebook978-0-230-58418-1
copyrightPalgrave Macmillan, a division of Macmillan Publishers Limited 2008
The information of publication is updating

書目名稱Leadership as Identity影響因子(影響力)




書目名稱Leadership as Identity影響因子(影響力)學科排名




書目名稱Leadership as Identity網(wǎng)絡公開度




書目名稱Leadership as Identity網(wǎng)絡公開度學科排名




書目名稱Leadership as Identity被引頻次




書目名稱Leadership as Identity被引頻次學科排名




書目名稱Leadership as Identity年度引用




書目名稱Leadership as Identity年度引用學科排名




書目名稱Leadership as Identity讀者反饋




書目名稱Leadership as Identity讀者反饋學科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 20:55:07 | 只看該作者
ation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
板凳
發(fā)表于 2025-3-22 00:41:10 | 只看該作者
地板
發(fā)表于 2025-3-22 06:22:24 | 只看該作者
Jackie Ford,Nancy Harding,Mark Learmonthation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
5#
發(fā)表于 2025-3-22 09:46:38 | 只看該作者
Jackie Ford,Nancy Harding,Mark Learmonthation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
6#
發(fā)表于 2025-3-22 16:26:49 | 只看該作者
7#
發(fā)表于 2025-3-22 18:50:45 | 只看該作者
8#
發(fā)表于 2025-3-22 22:49:25 | 只看該作者
Jackie Ford,Nancy Harding,Mark Learmonthation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
9#
發(fā)表于 2025-3-23 03:15:13 | 只看該作者
Jackie Ford,Nancy Harding,Mark Learmonthation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
10#
發(fā)表于 2025-3-23 06:55:57 | 只看該作者
Jackie Ford,Nancy Harding,Mark Learmonthation advice from the experts.The introduction of monoclonal antibodies revolutionized immunology. The development of human monoclonal antibodies was inspired primarily by the enormous clinical benefits promised by these reagents which can be used as anti-inflammatory reagents, anti-tumor reagents a
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 02:13
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
稷山县| 顺义区| 保定市| 盖州市| 宾阳县| 南通市| 文成县| 无棣县| 太仓市| 宜兰县| 克拉玛依市| 托克逊县| 防城港市| 兖州市| 绥芬河市| 曲阜市| 略阳县| 江川县| 桦南县| 商城县| 平凉市| 油尖旺区| 徐州市| 七台河市| 云和县| 乐安县| 东山县| 汶上县| 福州市| 樟树市| 平泉县| 金溪县| 大安市| 苍山县| 磐石市| 五台县| 苏尼特左旗| 蓝山县| 固始县| 涿州市| 江门市|